Cadrenal Therapeutics, Inc. (CVKD)
NASDAQ: CVKD · Real-Time Price · USD
7.33
+0.55 (8.11%)
At close: Jan 2, 2026, 4:00 PM EST
7.34
+0.01 (0.14%)
After-hours: Jan 2, 2026, 7:51 PM EST
Cadrenal Therapeutics Employees
Cadrenal Therapeutics had 4 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$3,596,410
Market Cap
17.14M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4 | 0 | - |
| Dec 31, 2023 | 4 | 1 | 33.33% |
| Dec 31, 2022 | 3 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CVKD News
- 3 days ago - Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response System - Accesswire
- 4 days ago - Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On - Accesswire
- 16 days ago - Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026 - GlobeNewsWire
- 21 days ago - Cadrenal's Quiet Expansion Play Is Starting to Get Loud - Accesswire
- 21 days ago - Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market - Accesswire
- 22 days ago - Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT) - GlobeNewsWire
- 4 weeks ago - Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors - GlobeNewsWire
- 6 weeks ago - Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida's Executive of the Year Award - GlobeNewsWire